^
    11ms
    2. #THOR: Erdafitinib vs chemo in advanced urothelial cancers in FGFR3/2alt (mut/fusion) - OS w/ erdafitinib 12.1 mos vs 7.8 mos (HR 0.64) - ORR favored erdafitinib arm 45.6% vs 11.5%, w/ 6.6% CR - AEs w/ #Erdafitinib: hyperphos, diarrhea, stomatitis #ASCO23 @apolo_andrea 4/9 (@OncBrothers)
    Metastases
    |
    FGFR3 (Fibroblast growth factor receptor 3)
    |
    FGFR3 fusion
    |
    Balversa (erdafitinib)
    1year
    Out in @NatureComms analysis of acquired resistance mechanisms to Osi in pts with EGFR-mut NSCLC from the AURA3 trial EGFR muts & MET amp occurred in 22% and 18% of pts, respectively. HER2 amp, MAPK/PI3K and fusions (FGFR3-TACC3, NTRK1-TMP3, RET-ERC1, https://t.co/4KFOPtlOnG… https://t.co/9beqyU0Qfj (@APassaroMD)
    Clinical
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • FGFR3 (Fibroblast growth factor receptor 3) • TACC3 (Transforming acidic coiled-coil containing protein 3) • ERC1 (ELKS/RAB6-Interacting/CAST Family Member 1)
    |
    NTRK1 fusion • FGFR3 fusion
    1year
    Dutcher bodies in an IgA‐myeloma patient harbouring the FGFR3/IGH fusion https://t.co/ZjAEf1HIj2 (@smbenlazar)
    Clinical
    |
    FGFR3 (Fibroblast growth factor receptor 3)
    |
    FGFR3 fusion
    almost2years
    For patients with solid tumors, there is a compassionate access program for erdafitinib, but i think that's for FGFR2 and FGFR3 fusions only. Tagging @drakhilkapoor1 for any additional information. (@VanitaNoronha)
    Clinical
    |
    FGFR2 (Fibroblast growth factor receptor 2) • FGFR3 (Fibroblast growth factor receptor 3)
    |
    FGFR2 fusion • FGFR3 fusion
    |
    Balversa (erdafitinib)
    almost4years
    A majority favor the Javelin Bladder 100 paradigm of gem-platinum followed by switch maintenance Avelumab for metastatic #UrothelialCarcinoma with somatic FGFR3/2 activating mutations/fusions-should we study switch maintenance FGFR inhibitor in this population? (@sonpavde)
    Clinical • PD(L)-1 Biomarker
    |
    FGFR3 (Fibroblast growth factor receptor 3)
    |
    FGFR3 mutation • FGFR3 fusion
    |
    Bavencio (avelumab)
    almost4years
    Sequencing therapy for metastatic #UrothelialCarcinoma:question to members of @asco @myESMO @BladderCancerUS:In post-platinum & PD1/L1 inh pts with FGFR3/2 mutations/fusions-if no contraindications/patient preferences for Erdafitinib or Enfortumab Vedotin, I advise initial: (@sonpavde)
    Clinical • PD(L)-1 Biomarker
    |
    FGFR3 (Fibroblast growth factor receptor 3) • PD-1 (Programmed cell death 1)
    |
    FGFR3 mutation • FGFR3 fusion
    |
    Balversa (erdafitinib) • Padcev (enfortumab vedotin-ejfv)